Our in vitro disease model research platform provides genetically edited iPSCs that retain
and can help facilitate the creation of isogenic cell line disease models.
Induced pluripotent stem cells (iPSCs) provide an ideal in vitro platform for studying disease mechanisms
and developing cell therapy approaches, as they can be derived from cells with a singular genetic
background and tailored to replicate specific disease phenotypes.
When combined with gene editing techniques, iPSCs can be used to explore the mechanisms of disease, and
develop effective new drugs and cell therapies. Cyagen’s iPSC disease model research platform has mature
gene editing technologies and stem cell culture systems; it has overcome many difficulties related to
iPSC cultivation, genetic modification, and monoclonalization.
Additionally, we provide one-stop preclinical CRO capabilities for developing new drugs and cell
therapies, including phenotype analysis, construction and testing of in vitro models for various disease
application scenarios, and even drug efficacy (pharmacokinetics/pharmacodynamic) evaluations. You are
welcome to contact
us at 800-921-8930 or email to email@example.com for